Table 3 Experiences and satisfaction with nintedanib and pirfenidone after three and six months of antifibrotic treatment

1.7 (1.6)

1.5 (1.6)

0.2 (− 0.5–0.9)

0.58

1.4 (1.7)

1.7 (1.9)

0.3 (− 1.1–0.6)

0.54

1.7 (2.0)

1.8 (2.2)

0.1 (− 1–0.9)

0.9

1.3 (1.9)

1.8 (2.2)

0.4 (− 1.4–0.5)

0.37

Satisfaction with ease of use

3.2 (1.6)

2.6 (1.6)

0.6 (− 0.1–1.3)

0.08

2.9 (1.4)

2.5 (1.9)

0.4 (−0.4–1.1)

0.3

Overall satisfaction with medication

2.2 (1.7)

1.9 (1.8)

0.2 (−0.5–1)

0.53

1.9 (1.7)

2.2 (2.0)

0.2 (−1.1–0.6)

0.58

1.7 (1.0)

1.7 (0.9)

0.09 (−0.7–0.5)

0.75

2 (1.1)

1.8 (1.0)

0.2 (− 0.6–1)

0.55

3.1 (1.2)

2.9 (1.2)

0.3 (−0.3–0.8)

0.41

2.8 (1.2)

3.1 (1.1)

0.3 (−0.8–0.2)

0.25

3.9 (0.3)

3.8 (0.5)

0.1 (−0.05–0.3)

0.14

3.9 (0.3)

03.7 (0.6)

0.1 (−0.07–0.4)

0.18

6.0 (3.5)

6.6 (4.6)

0.6 (−2.4–1.3)

0.55

5.7 (4.2)

5.7 (5.1)

0.05 (−2–2.1)

0.96

9.9 (13.2)

9.8 (9.3)

0.1 (−4.8–5.1)

0.96

8.9 (9.5)

8.3 (9.0)

0.6 (−3.3–4.5)

0.75